InvestorsHub on MSN

Theralase and Ferring ink deal for new bladder cancer study

Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the ...
Renal & Urology News

Ta Low-Grade NMIBC Recurrence Not Uncommon After 5 Years

Approximately 1 in 10 patients with Ta low-grade NMIBC recurred after 5 years warrant continued surveillance. Nearly 10% of patients initially diagnosed with Ta low-grade nonmuscle-invasive bladder ...
Business Wire

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, a pioneer in AI-powered diagnostics for oncology, announced the publication of its latest research in European Urology, the highest-impact journal in ...
Targeted Oncology

A Paradigm Shift in Bladder Cancer: Dr Jacob on the FDA Approval of TAR-200

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have ...